<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; it</title>
	<atom:link href="http://www.tapanray.in/tag/it/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Exigency of Cybersecurity in Digitalized Pharma</title>
		<link>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exigency-of-cybersecurity-in-digitalized-pharma</link>
		<comments>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/#comments</comments>
		<pubDate>Mon, 08 Oct 2018 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[cybersecurity]]></category>
		<category><![CDATA[digitalized]]></category>
		<category><![CDATA[digitized]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[espionage]]></category>
		<category><![CDATA[exigency]]></category>
		<category><![CDATA[experienced]]></category>
		<category><![CDATA[hack]]></category>
		<category><![CDATA[hacking]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9204</guid>
		<description><![CDATA[Digitalization – as it unfolds and imbibed by most drug companies, is presumed to herald a whole new ballgame in the Indian pharma business. Equally significant is the quantum benefit that the process will deliver to pharma stakeholders – right &#8230; <a href="http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quantum Value Addition With Health Apps, Going Beyond Drugs</title>
		<link>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quantum-value-addition-with-health-apps-going-beyond-drugs</link>
		<comments>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/#comments</comments>
		<pubDate>Mon, 30 Mar 2015 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Betaseron]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health Apps]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[mApps]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[myBETAapp]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Podhaler Pro]]></category>
		<category><![CDATA[Pradaxa Health App]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tracker]]></category>
		<category><![CDATA[Xarelto Patient Care App]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6475</guid>
		<description><![CDATA[Besides all important brand attributes and how well those are communicated to the doctors, the &#8216;game winning&#8217; differentiating factors in the prescription drug business, as it appears today, would revolve around overall quality of patient-centric approach and offerings of pharma &#8230; <a href="http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quantum-value-addition-with-health-apps-going-beyond-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama Wins: ‘Obamacare’ stays on course… and what it means to India?</title>
		<link>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=obama-wins-obamacare-stays-on-course-and-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 12 Nov 2012 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[on course]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[stays]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[what]]></category>
		<category><![CDATA[Wins]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1069</guid>
		<description><![CDATA[Re-election of President Barrack Obama for another four year term, no doubt, sends a clear signal to all concerned that full implementation of the ‘Patient Protection and Affordable Care Act’ of America, which is also known to many as ‘Obamacare’, &#8230; <a href="http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/obama-wins-obamacare-stays-on-course-and-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>e-healthcare: A new vista to improve access to quality and affordable healthcare in India</title>
		<link>http://www.tapanray.in/e-healthcare-a-new-vista-to-improve-access-to-quality-and-affordable-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=e-healthcare-a-new-vista-to-improve-access-to-quality-and-affordable-healthcare-in-india</link>
		<comments>http://www.tapanray.in/e-healthcare-a-new-vista-to-improve-access-to-quality-and-affordable-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 09 May 2011 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[e-healthcare]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISRO]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[vista]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=261</guid>
		<description><![CDATA[The concept of e-healthcare started germinating in India since 1999, when the ‘Indian Space Research Organization (ISRO)’ initiated its pioneering step towards telemedicine in the country by deploying a SATCOM-based telemedicine network. This network is currently playing a key role &#8230; <a href="http://www.tapanray.in/e-healthcare-a-new-vista-to-improve-access-to-quality-and-affordable-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/e-healthcare-a-new-vista-to-improve-access-to-quality-and-affordable-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissapointing: No proposal of &#8216;Healthcare Reform&#8217; in the Union Budget of India for 2011-12: China rolled it out in 2009.</title>
		<link>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009</link>
		<comments>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/#comments</comments>
		<pubDate>Mon, 28 Feb 2011 00:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2009]]></category>
		<category><![CDATA[2011-12]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[adequate]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Disappointing]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[inadequate]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[of pocket]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[rolled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=296</guid>
		<description><![CDATA[January 15, 2011 issue of ‘The Lancet’ in an article titled, “Learning from others” states the following: “Having universal coverage through a public commitment does have costs, including public costs. The proportion of national expenditure on health that is met &#8230; <a href="http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dissapointing-no-proposal-of-healthcare-reform-in-the-union-budget-of-india-for-2011-12-china-rolled-it-out-in-2009/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescribing medicines by generic names…a good intent… but is it a practical proposition in India?</title>
		<link>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india</link>
		<comments>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/#comments</comments>
		<pubDate>Mon, 06 Sep 2010 00:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[chemists]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proposition]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=378</guid>
		<description><![CDATA[Parliamentary Standing Committee for Health and Family Welfare in their recommendation to the ‘Rajya Sabha’ of the Indian Parliament on August 4, 2010, recommended prescription of medicines by their generic names. This recommendation appears to be based on the premises &#8230; <a href="http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ‘Climate Change’ and its impact on ‘Public health’: is there anything in it that we can do ourselves?</title>
		<link>http://www.tapanray.in/the-climate-change-and-its-impact-on-public-health-is-there-anything-in-it-that-we-can-do-ourselves/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-climate-change-and-its-impact-on-public-health-is-there-anything-in-it-that-we-can-do-ourselves</link>
		<comments>http://www.tapanray.in/the-climate-change-and-its-impact-on-public-health-is-there-anything-in-it-that-we-can-do-ourselves/#comments</comments>
		<pubDate>Mon, 01 Mar 2010 02:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[anything]]></category>
		<category><![CDATA[can]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[ourselves]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[that]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[we]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=461</guid>
		<description><![CDATA[The Lancet in its December 5, 12 and 19, 2009 issues published the following interesting studies:A. Public health benefits of strategies to reduce greenhouse-gas emissions: household energy B. Public health benefits of strategies to reduce greenhouse-gas emissions: urban land transport &#8230; <a href="http://www.tapanray.in/the-climate-change-and-its-impact-on-public-health-is-there-anything-in-it-that-we-can-do-ourselves/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-climate-change-and-its-impact-on-public-health-is-there-anything-in-it-that-we-can-do-ourselves/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patent offices (IPOs) have started showing improvement in their functioning; still lot of grounds to cover.</title>
		<link>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover</link>
		<comments>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/#comments</comments>
		<pubDate>Thu, 10 Dec 2009 01:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CGPDTM]]></category>
		<category><![CDATA[cover]]></category>
		<category><![CDATA[functioning]]></category>
		<category><![CDATA[grounds]]></category>
		<category><![CDATA[Have]]></category>
		<category><![CDATA[improvement]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[lot]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offices]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[showing]]></category>
		<category><![CDATA[started]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=700</guid>
		<description><![CDATA[Indian Patent offices are located, with four clearly specified jurisdictions, at New Delhi, Mumbai, Kolkata and Chennai. Since last few years enough efforts have been made towards overall capacity building initiatives, training of personnel and digitalizing the huge databank of &#8230; <a href="http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patent-offices-ipos-have-started-showing-improvement-in-their-functioning-still-lot-of-grounds-to-cover/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Contract Research – a rapidly evolving business opportunity in India: Is the Pharmaceutical Industry making the best use of it?</title>
		<link>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it</link>
		<comments>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 01:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Contract]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[evolving]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rapidly]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[use]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=845</guid>
		<description><![CDATA[A quick perspective of the ‘new-era’ pharmaceutical R&#38;D in India: Since 1970 up until 2005, Indian pharmaceutical industry used to be considered as the industry of ‘reverse engineering’ and that too with an underlying disparaging tone&#8230; and also as the &#8230; <a href="http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/contract-research-a-rapidly-evolving-business-opportunity-in-india-is-the-pharmaceutical-industry-making-the-best-use-of-it/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
